YOLFTbeta
Annexon Inc

Annexon Inc

ANNX · NASDAQ · Healthcare / Biotechnology

3.92USD-0.05 (-1.26%)

Price History

Full chart

Market Stats

Previous Close3.97
Open3.97
Day Range3.74 – 3.99
52-Week Range2.54 – 7.18
Volume2.58M
Market Cap720.40M
P/E (TTM)0.00
Forward P/E0.00
EPS-1.11
Dividend Yield0.00%
Beta1.22
50-Day Avg4.99
200-Day Avg5.39

About

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Douglas E. Love Esq., J.D.
  • Employees92
  • Headquarters1400 Sierra Point Parkway, Brisbane, CA, United States, 94005, USA
  • Websitehttps://www.annexonbio.com

Leadership

  • Mr. Douglas E. Love Esq., J.D.CEO, President & Director · b. 1968
  • Ms. Jennifer Lew CPAExecutive VP, CFO & Corporate Secretary · b. 1973
  • Dr. Ted Yednock Ph.D.Executive VP, Chief Innovation Officer & Chairman of the Scientific Advisory Board · b. 1958
  • Dr. Dean R. Artis Ph.D.Chief Scientific Officer & Executive VP · b. 1961
  • Ms. Linda A. FitzpatrickChief Human Resources Officer · b. 1957
  • Mr. Michael Overdorf M.B.A.Executive VP & Chief Business Officer · b. 1971
  • Mr. Henk-Andre Kroon M.D.Senior Vice President of Translational Medicine
  • Dr. Jamie Dananberg M.D.Executive VP & Chief Medical Officer · b. 1958
  • Mr. Shikhar Agarwal M.B.A.Senior VP & Head of Commercial
  • Dr. Sunil Mehta Pharm.D.Senior VP of Medical Affairs

Financials

Income Statement

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-00000000
Cost of Revenue271.00K488.00K493.00K667.00K3.41M3.31M3.27M3.45M3.69M
Gross Profit-271.00K-488.00K-493.00K-667.00K-3.41M-3.31M-3.27M-3.45M-3.69M
Operating Expense20.21M18.66M32.02M62.80M127.30M142.29M140.46M150.62M212.72M
Operating Income-20.48M-19.15M-32.52M-63.47M-130.71M-145.60M-143.72M-154.07M-216.41M
EBITDA-20.21M-18.66M-32.02M-62.80M-128.57M-143.49M-132.09M-134.75M-204.04M
Net Income-18.71M-18.30M-37.18M-62.74M-127.79M-138.29M-134.24M-138.20M-206.69M
R&D17.85M15.53M24.52M49.27M100.07M112.50M113.76M119.45M184.70M
Interest Expense004.66M02.14M3.65M---

Balance Sheet

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets7.82M48.15M49.90M355.95M287.04M285.10M297.67M350.07M277.57M
Total Liabilities54.03M10.27M6.37M11.67M55.13M53.90M47.12M56.97M65.92M
Total Equity-46.21M37.88M43.53M344.28M231.91M231.19M250.56M293.11M211.65M
Cash2.97M44.17M43.93M268.56M74.84M140.02M225.11M49.50M162.05M
Total Debt48.97M107.22M--34.59M32.86M31.36M28.97M26.20M
Net Debt46.01M63.05M-43.93M-268.56M-40.25M-107.16M-193.75M-20.53M-135.85M

Cash Flow

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-19.26M-17.19M-28.36M-53.09M-106.11M-116.31M-121.14M-118.01M-186.36M
Investing Cash Flow-567.00K-17.00K-267.00K-83.16M-88.24M58.44M70.70M-218.80M190.05M
Financing Cash Flow42.00K58.46M28.39M360.88M1.79M122.91M135.52M161.21M108.86M
Capital Expenditure567.00K17.00K267.00K464.00K1.65M6.53M193.00K15.00K137.00K
Free Cash Flow-19.83M-17.21M-28.63M-53.55M-107.76M-122.83M-121.33M-118.02M-186.49M
Dividends Paid---102.52M----1.86M
FCF to OCF102.94%100.10%100.94%100.87%101.56%105.61%100.16%100.01%100.07%
Dividend Paid to FCF----191.45%-----1.00%

Earnings

Report DateSep 18, 2019Dec 6, 2019Jun 3, 2020Sep 8, 2020Nov 16, 2020Mar 25, 2021May 17, 2021Aug 16, 2021Nov 9, 2021Mar 1, 2022May 9, 2022Aug 8, 2022Nov 3, 2022Mar 6, 2023May 8, 2023Aug 7, 2023Nov 13, 2023Mar 26, 2024May 13, 2024Aug 12, 2024Nov 14, 2024Mar 24, 2025May 12, 2025Aug 14, 2025Nov 10, 2025Mar 9, 2026May 7, 2026Aug 12, 2026Nov 9, 2026
EPS Estimate0.000.00-2.13-0.53-0.35-0.44-0.65-0.68-0.88-0.92-1.03-0.95-0.92-0.53-0.52-0.54-0.51-0.44-0.35-0.24-0.27-0.29-0.29-0.36-0.34-0.32-0.30-0.23-0.28
EPS Actual-0.05-0.06-3.30-28.87-0.58-0.61-0.68-0.82-0.93-0.97-0.92-0.96-0.51-0.48-0.52-0.47-0.43-0.36-0.21-0.23-0.25-0.33-0.37-0.34-0.37-0.28-0.23-0.28-
Surprise---54.93%-5347.17%-65.71%-38.64%-4.62%-20.59%-5.68%-5.43%10.68%-1.05%44.57%9.43%0.00%12.96%15.69%18.18%40.00%4.17%7.41%-12.51%-27.59%5.56%-8.82%12.47%23.33%-21.74%-
Timing---After-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hours-After-hoursPre-marketPre-market

Key Statistics & Ratios

Market Cap720.40M
Enterprise Value549.08M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book3.94
EPS-1.11
Book Value1.07
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-208.39M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-105.26%
Return on Assets-51.54%
Shares Outstanding189.58M
Shares Float163.79M
Beta1.22
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 8 analystsTarget 15.29
  • Strong Buy
    5
  • Buy
    3

Ownership Breakdown

Institutions
103.01%
Insiders
0.42%
Retail / Other
0.00%

Top Institutional Holders

  • Redmile Group, LLC
    11.87M6.26%
  • BlackRock Inc
    10.94M5.77%
  • FMR Inc
    10.64M5.61%
  • Bvf Inc
    8.70M4.59%
  • State Street Corp
    6.92M3.65%
  • Vanguard Capital Management, LLC
    5.96M3.14%
  • Bain Capital Life Sciences Investors, LLC
    5.21M2.75%
  • Bellevue Group AG
    5.16M2.72%
  • Mak Capital One LLC
    4.72M2.49%
  • Bank of America Corp
    4.26M2.25%
  • Nuveen, LLC
    4.25M2.24%
  • Siren, L.L.C.
    3.96M2.09%
  • Balyasny Asset Management LLC
    3.89M2.05%
  • MPM Oncology Impact Management LP
    3.54M1.87%
  • Adage Capital Partners Gp LLC
    3.50M1.85%
  • Great Point Partners LLC
    3.50M1.85%

Top Fund Holders

  • State Street® SPDR® S&P® Biotech ETF
    6.58M3.47%
  • Fidelity Select Biotechnology
    6.17M3.26%
  • Vanguard MStar Total Stk Mkt Idx Invest
    4.97M2.62%
  • iShares Russell 2000 ETF
    4.00M2.11%